Episynchrons for precision medicine

Abstract

This invention relates to the field of peptide diagnostics and therapeutics, and more particularly to novel structures and uses of a ligand-modified species of immodulin peptides herein termed “episynchrons”—end-modified immodulin peptides capable of driving the enhanced formation of RXR heterodimers in the nucleus of living mammalian cells—to modulate immunoregenerative processes, among other uses. The covalent addition of the exemplified nuclear receptor ligands to the carboxyterminus of a peptide prior to full chain elongation during peptide synthesis is novel and relevant to the cost of production of these agents at scale. Moreover, the facile and organelle-specific ‘on-demand’ reprogramming of transcriptional sets within target tissues is a technical breakthrough relevant to the future of precision medicine. Pre-designed tissue-specific epigenetic synchrony made possible by the unique structure of episynchrons in combination with the formulation of episynchrons in zip-coded microparticles or nanoparticles delivered in a location-specific manner, is a powerful and novel concept for twenty-first century medicine. The compositions and methods provided herein demonstrate new and surprising biological activities for episynchrons that are useful in treating a wide range of dysfunctions and perturbations in mammals in the context of organ- and stress-specific precision medicine.

Dependencies are inferred from the claim text.